The trajectory of companies tied to Sildenafil's history presents a intricate investment scenario . While the initial success generated substantial gains, generic competition have significantly eroded market share . Investing in connected pharmaceutical companies now requires a discerning assessment of proprietary safeguards, evolving patient shift